ARGX Stock Overview
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €368.60 |
| 52 Week High | €550.76 |
| 52 Week Low | €327.73 |
| Beta | 0.36 |
| 1 Month Change | -7.52% |
| 3 Month Change | -3.66% |
| 1 Year Change | -4.97% |
| 3 Year Change | 28.56% |
| 5 Year Change | 190.49% |
| Change since IPO | 1,502.61% |
Recent News & Updates
Recent updates
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals
Jun 07Argenx raises ~$1B in global offering
Feb 03argenx to raise $750M in proposed global offering
Feb 01argenx on target to file efgartigimod applications in Japan and Europe
Jan 08argenx and Zai Lab collaborate for Efgartigimod in Greater China
Jan 06Argenx inks $98M deal to secure accelared review status for efgartigimod
Nov 23argenx (ARGX) Investor Presentation - Slideshow
Nov 18Shareholder Returns
| ARGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.3% | 0.4% | 1.0% |
| 1Y | -5.0% | 0.9% | 21.9% |
Return vs Industry: ARGX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: ARGX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARGX has not had significant price volatility in the past 3 months.
Volatility Over Time: ARGX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,148 | Tim Van Hauwermeiren | www.argenx.com |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
argenx SE Fundamentals Summary
| ARGX fundamental statistics | |
|---|---|
| Market cap | US$22.05b |
| Earnings (TTM) | -US$295.05m |
| Revenue (TTM) | US$1.27b |
17.4x
P/S Ratio-74.7x
P/E RatioIs ARGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARGX income statement (TTM) | |
|---|---|
| Revenue | US$1.27b |
| Cost of Revenue | US$977.33m |
| Gross Profit | US$291.27m |
| Other Expenses | US$586.32m |
| Earnings | -US$295.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -4.97 |
| Gross Margin | 22.96% |
| Net Profit Margin | -23.26% |
| Debt/Equity Ratio | 0% |
How did ARGX perform over the long term?
See historical performance and comparison